Abstract
Metformin, the primary therapy for type 2 diabetes mellitus (T2DM), showed limitations such as varying absorption, rapid system clearance, required large amount, resistance, longstanding side effects. Use of Nano formulations for pharmaceuticals is emerging as a viable technique to reduce negative consequences of drug, while simultaneously attaining precise release and targeted distribution. This study developed a Polyethylene Glycol conjugated Graphene Oxide Quantum dots (GOQD-PEG) nanocomposite for the sustained release of metformin. Herein, we evaluated the effectiveness of metformin-loaded nanoconjugate in in vitro insulin resistance model. Results demonstrated drug loaded nanoconjugate successfully restored glucose uptake and reversed insulin resistance in in vitro conditions at reduced dosage compared to free metformin.
Funder
Princess Nourah Bint Abdulrahman University
Publisher
Public Library of Science (PLoS)
Reference40 articles.
1. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives;J Reed;Diabetes, Metabolic Syndrome and Obesity,2021
2. Global estimates of diabetes prevalence for 2013 and projections for 2035;L Guariguata;Diabetes research and clinical practice,2014
3. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus;JC Ozougwu;J Physiol Pathophysiol,2013
4. Combination of metformin with other antioxidants may increase its renoprotective efficacy;M Rafieian-Kopaei;Journal of renal injury prevention,2013
5. Metformin and its benefits for various diseases;Z Lv;Frontiers in endocrinology,2020